Fosamax Lawsuits: Bernstein Liebhard LLP Notes Opening Statements Set to Begin in First Federal Fosamax Femur Fracture Trial on April 9th

Share Article

The Firm continues to investigate Fosamax lawsuits on behalf of individuals who allegedly suffered Fosamax femur fractures due to long-term use of the drug.

Bernstein Liebhard LLP | Consumer Injury Lawyers
We continue to hear from women who suffered serious and debilitating femur fractures, allegedly due to their long-term use of Fosamax. We look forward to the start of this trial.

Fosamax lawsuits involving femur fracture allegations continue to make their way through state and federal courts, Bernstein Liebhard LLP reports. Court records indicate opening statements in the first trial of hundreds of Fosamax femur fracture claims pending in U.S. District Court, District of New Jersey, are scheduled to begin on April 9th.    According to a recent report, at least 850 Fosamax femur fracture cases are pending in the federal litigation.* (In re: Fosamax (Alendronate Sodium) Products Liability Litigation (No. II) - MDL No. 2243)

“We continue to hear from women who suffered serious and debilitating femur fractures, allegedly due to their long-term use of Fosamax. We look forward to the start of this trial,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices, including dozens of women allegedly suffering injuries as a result of Fosamax. The Firm is currently offering free legal evaluations to alleged victims of Fosamax femur fractures.

Fosamax Femur Fracture Lawsuits
According to the Bloomberg report, Merck & Co. is named a defendant in more than 3,300 Fosamax femur fracture claims. In addition to those pending in New Jersey federal court, more than 2,000 additional Fosamax lawsuits involving femur fracture allegations have been filed in a consolidated litigation underway in New Jersey Superior Court, Atlantic County, said. Bernstein Liebhard LLP is actively filing Fosamax lawsuits in the New Jersey state litigation. (In re: Fosamax Litigation, No. 282, N.J. Super. Ct) Last month, the first Fosamax femur facture lawsuits to go to trial in the New Jersey state litigation was declared a mistrial, after the plaintiff became ill. Court documents do not indicate when that case might be rescheduled for trial. (Su v. Merck Sharp & Dohme Corp., case number ATL-L-0789-11)

Fosamax femur fracture claims have been mounting since October 2010, when the U.S. Food & Drug Administration (FDA) cautioned that some studies had indicated patients taking bisphosphonates for osteoporosis were at heightened risk for atypical femur fractures. Among other things, the FDA advised doctors to consider periodic reevaluation of bisphosphonate therapy, particularly in patients who have been treated for over 5 years.**

Victims of alleged Fosamax femur fractures may be entitled to compensation for medical bills, lost wages, pain and suffering, and other damages. A wealth of information regarding Fosamax lawsuits is available by visiting Bernstein Liebhard LLP’s website, To arrange for a free case review, please contact Bernstein Liebhard LLP at (877) 779-1414.


About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website